Yes, if I remember rightly I thought they said they'd been having challenges recruiting enough patients to the PW trial due to competing trials of other drugs as well as the onerous safety protocol of running the Ph 2. I'm guessing the onerous safety protocol may have required lots of regular travel to testing locations, etc, which I could imagine might put people off.
There was comment that a reduced safety protocol would make recruitment easier, as you say. So this does at face value provide a good reason for discontinuing the trial.
Whether Neuren restart it is another question. If their new clinical studies indicates there are now better options to go for (ones with less competition than PW, which is becoming a crowded space), then it might make better sense to focus on them instead. The best strategy forward from today may be quite different than the one Neuren originally planned from two years ago.
All this might become moot of course if there's a near term low-ball TO offer the Neuren board plans to accept....
NEU Price at posting:
$13.46 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)